A struggle to SURVIVE: to abandon or not to abandon levosimendan?

Cardiovasc Drugs Ther. 2007 Oct;21(5):401-2. doi: 10.1007/s10557-007-6046-y.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acute Disease
  • Cardiotonic Agents / administration & dosage*
  • Cardiotonic Agents / therapeutic use
  • Dobutamine / administration & dosage
  • Dobutamine / therapeutic use
  • Heart Failure / drug therapy*
  • Humans
  • Hydrazones / administration & dosage*
  • Hydrazones / therapeutic use
  • Natriuretic Peptide, Brain / blood
  • Natriuretic Peptide, Brain / drug effects
  • Pyridazines / administration & dosage*
  • Pyridazines / therapeutic use
  • Simendan
  • Survival Rate
  • Treatment Outcome

Substances

  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Natriuretic Peptide, Brain
  • Simendan
  • Dobutamine